Today

Agents

Chat

Arena

Discover

More

App

Castle Biosciences CEO Derek Maetzold disposes of $202,507 in common shares - CSTL News | Rallies

Castle Biosciences CEO Derek Maetzold disposes of $202,507 in common shares

CSTL•2026-07-29

CEO share sale and option exercise

Castle Biosciences CEO Derek J. Maetzold sold 6,214 shares on July 27, 2026, cutting his direct stake to 21,479 shares.
Sales were priced at USD 24.13 and USD 25.06, totaling 7,521 shares across direct holdings and family trusts.
He also exercised stock options for 6,214 shares at USD 2.39.

Related News

Smartbird replaces Deloitte with BPM as auditor after RFP process

BIRD•2026-07-29

Service Corporation Q2 beats estimates on higher prices; narrows FY profit view

SCI•2026-07-29

FMC Q2 adjusted EPS beats estimates, cuts FY outlook

Sources

S

Castle Biosciences CEO Derek Maetzold disposes of $202,507 in common shares

Sec

2026-07-29

Quaker Houghton raises quarterly dividend to $0.53 a share

KWR•2026-07-29

Dakota Gold names Jack Henris CEO as Quartermain retires in August 2026

DC•2026-07-29